Live healthier, stronger and sharper for longer
Short, frequent pieces on what changed in the science of ageing well — and our research library holds the deep dives.
PeptidesSS-31 (Elamipretide) in 2026: Latest Clinical
A deep dive into SS-31 (Elamipretide)'s most recent clinical findings, focusing on 2025-2026 data and its implications for longevity and healthspan.
PeptidesSS-31 (Elamipretide): Latest Evidence and 2026
Explore the cutting-edge science behind SS-31 (Elamipretide), with a focus on breakthroughs from 2025-2026 and its potential in healthy ageing.
PeptidesIpamorelin in the UK: Availability, Cost, and
Demystifying Ipamorelin's landscape in the UK, this post offers a comprehensive guide to its availability, pricing, legal status, and reputable sourcing channels for 2026.
PeptidesSS-31 (Elamipretide) in 2026: Unpacking the
SS-31 (Elamipretide) continues to garner attention for its mitochondrial-targeting properties. We delve into the newest clinical data and revised insights for 2026.
PeptidesSS-31 (Elamipretide) Latest Evidence 2026: A
This updated review focuses on the latest 2025-2026 evidence for SS-31 (Elamipretide), dissecting new clinical trials and their implications for longevity and mitochondrial health.
PeptidesSS-31 Dosing & Protocol Optimisation for
Demystifying SS-31 dosing is crucial for maximising its mitochondrial benefits. We break down protocols for longevity, performance, and recovery, informed by the latest research.
PeptidesSS-31 (Elamipretide): Latest Clinical Evidence
A deep dive into the newest 2025-2026 clinical data on SS-31 (Elamipretide), revisiting its potential for mitochondrial health and assessing its place in longevity protocols.
Wondering where to start?
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
The Sunday briefing
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.